We are proud to announce that the project “Development and Application of an Optoelectronic Microfluidic Platform”, led by OptoSeeker’s Chief Scientist Prof. Shuailong Zhang, has been officially selected for funding under the 2024 Key Program of China’s National Key R&D Plan in “Frontier Biotechnology”, with a grant amount nearing 20 million RMB!
The “Frontier Biotechnology” program is a prestigious national initiative aimed at achieving breakthroughs in disruptive biotechnologies, enhancing China’s original innovation capacity in life sciences, and driving a revolution in the biotech industry. Prof. Zhang’s team aligns closely with national strategic priorities, focusing on next-generation optoelectronic microfluidics to develop intelligent cell screening platforms that overcome industry bottlenecks and dramatically improve screening precision and efficiency.
This cutting-edge technology is already being deployed in OptoSeeker’s new generation of optoelectronic tweezer single-cell screening products, marking another milestone in the company’s path of national recognition and technological leadership.
National-Level Recognition Underscores OptoSeeker’s Core Strengths
1.Technological Leadership:
Bridging the gap in domestic intelligent cell screening platforms with groundbreaking innovations.
2. Commercial Impact:
Empowering the industry through dual-output of platform technologies and hardware solutions.
3. Strategic Vision:
Harnessing interdisciplinary expertise to seize high ground in next-gen biotech.
OptoSeeker will continue to join hands with global partners to advance the application of optoelectronic microfluidics, accelerate the upgrade of the biopharmaceutical industry, and deliver more efficient, innovative therapies to patients worldwide — contributing the power of China to global healthcare innovation!
